Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Details on the H.C. Wainwright fireside chat presentation are as follows:
A webcast link to the fireside chat presentation will be accessible on the Events section of the Altimmune website.
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Investor & Media Contacts:
Chief Financial Officer
Source: Altimmune, Inc